Urogen Pharma (NASDAQ:URGN) Posts Earnings Results, Beats Estimates By $0.03 EPS

Urogen Pharma (NASDAQ:URGN) announced its quarterly earnings data on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03, Zacks reports. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The company had revenue of $27.48 million for the quarter, compared to the consensus estimate of $34.09 million.

Urogen Pharma Stock Performance

NASDAQ URGN traded up $4.23 on Thursday, reaching $23.54. The company’s stock had a trading volume of 4,246,248 shares, compared to its average volume of 1,455,561. The firm’s 50 day moving average is $18.52 and its two-hundred day moving average is $14.93. The stock has a market cap of $1.09 billion, a PE ratio of -7.09 and a beta of 1.06. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $23.64.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider owned 148,229 shares in the company, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 1,520 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the transaction, the general counsel owned 43,305 shares in the company, valued at $827,558.55. This represents a 3.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 14,594 shares of company stock worth $259,713. Company insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC increased its position in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after purchasing an additional 1,968 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Urogen Pharma by 79.7% in the 2nd quarter. Marshall Wace LLP now owns 20,660 shares of the company’s stock valued at $283,000 after buying an additional 9,160 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on URGN. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen downgraded Urogen Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Urogen Pharma in a report on Monday, October 27th. Finally, Piper Sandler assumed coverage on shares of Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price objective for the company. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.